Karen has spent more than 25 years launching, funding and building life science and medical technology companies. Most recently, Karen was the Chief Executive Officer of Redwood Bioscience which she joined as the first non-founder employee in 2009, leading the company through its acquisition by Catalent (CTLT) in 2014. Redwood pioneered protein-chemical conjugation and linker technologies that provide control over the uniformity, architecture and stability of drug conjugates. Pharmaceutical companies are employing the platform in their therapeutics to enhance conjugate potency and delivery to tumors and other disease targets with fewer side effects. Prior to joining Redwood, Karen co-founded and was a Partner with Thomas, McNerney & Partners, a med tech-focused venture firm with $600 million under management. Previously, she was a General Partner of Coral Ventures and a member of Warburg Pincus LLC’s health care technology venture group. During her venture career, Karen was involved with 15 companies from initial investment that went public and/or were acquired. She was responsible for launching three of those companies in collaboration with their scientific founders, all of which were acquired. Prior to joining Warburg, Karen was a member of Alex. Brown & Sons’s health care and insurance corporate finance teams, with a focus on fundraising for biotechnology and health care service companies and insurance mergers & acquisitions. She graduated Phi Beta Kappa with a B.S. from the Wharton School at the University of Pennsylvania.